Salehiya Trading Company

Salehiya Trading Company, established in 1964, is a prominent Saudi Arabian entity specializing in the distribution of pharmaceuticals, medical equipment, and patient and consumer care products. Headquartered in Riyadh, the company has expanded its operations to include branches in Jeddah, Dammam, Khamis Mushait, Qassim, and Medina Al-Munawarah, ensuring comprehensive coverage across the Kingdom.

As a private joint-stock company, Salehiya Trading Company plays a pivotal role in Saudi Arabia's pharmaceutical supply chain, acting as a primary wholesaler and distributor. The company collaborates with international partners to import and distribute a diverse range of pharmaceutical products, medical devices, and consumer health items, thereby enhancing the healthcare experience within the Kingdom.

Salehiya Trading Company operates an extensive distribution network with its headquarters in Riyadh and additional branches in Jeddah, Dammam, Khamis Mushait, Qassim, and Medina Al-Munawarah. This strategic placement enables the company to effectively serve clients across Saudi Arabia. The company has been certified by SGS for compliance with World Health Organization (WHO) Good Distribution Practices (GDP), establishing it as a leader in the warehousing and transportation of pharmaceutical products within the Kingdom.

In Saudi Arabia's pharmaceutical supply chain, Salehiya Trading Company serves as a primary wholesaler and distributor. By importing and distributing a diverse range of pharmaceutical products, medical devices, and consumer health items, the company plays a crucial role in enhancing the healthcare experience within the Kingdom.

Salehiya Trading Company's sourcing strategy exhibits a high degree of concentration, with a total import value of $3.3 million USD from India across 119 shipments. The top five imported products—Meropenem, Vincristine, and Dacarbazine—account for 100% of the company's imports from India. This indicates a strategic focus on specific therapeutic areas, particularly advanced antibiotics and oncology treatments.

The company's reliance on a limited number of suppliers—GLENMARK PHARMACEUTICALS LIMITED, VENUS REMEDIES LIMITED, and CIPLA LIMITED—suggests a stable and possibly long-term relationship with these partners. However, this concentration also presents potential risks, such as supply chain disruptions or pricing volatility. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

Salehiya Trading Company's supply chain resilience is closely tied to its partnerships with Indian suppliers. The company's focus on a limited number of suppliers for its top imported products indicates a stable relationship, which is beneficial for consistent product availability. However, this concentration also exposes the company to potential risks, such as supply chain disruptions or pricing volatility. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

Salehiya Trading Company's concentrated sourcing strategy positions it as a key player in the Saudi Arabian market for advanced antibiotics and oncology treatments. This focus allows the company to leverage specialized expertise and establish strong relationships with its suppliers. For Indian exporters, this presents an opportunity to strengthen existing partnerships and explore avenues for diversification within Salehiya's product portfolio. However, potential suppliers should be aware of the risks associated with high supplier concentration and consider strategies to mitigate these risks.

The Saudi Food and Drug Authority (SFDA) is the primary regulatory body overseeing the pharmaceutical sector in Saudi Arabia. The SFDA is responsible for regulating the import, registration, and distribution of pharmaceutical products, ensuring they meet the Kingdom's health and safety standards. The Law of Pharmaceutical Establishments and Products (2023), issued under Royal Decree No. M/108, provides the legal framework governing medicinal products, herbal preparations, and pharmaceutical operations in the Kingdom.

Importing pharmaceutical products into Saudi Arabia requires compliance with specific licensing and certification requirements. A Certificate of Free Sale from the exporting country's Department of Health and Human Services is mandatory for all pharmaceutical shipments. Additionally, the Saudi Food and Drug Authority (SFDA) mandates that imported pharmaceutical products be registered and approved before entering the Saudi market. The SFDA also recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S), ensuring that imported products meet high-quality standards.

Imported pharmaceutical products must undergo batch testing and meet stability requirements as stipulated by the Saudi Food and Drug Authority (SFDA). Labeling must be in Arabic, including essential information such as product name, dosage form, strength, and usage instructions. Serialization mandates are enforced to enhance traceability and prevent counterfeit products from entering the market. These regulations ensure that pharmaceutical products in Saudi Arabia are safe, effective, and of high quality. (beta.sfda.gov.sa)

Between 2024 and 2026, Saudi Arabia implemented several regulatory changes affecting pharmaceutical imports. The Law of Pharmaceutical Establishments and Products (2023), issued under Royal Decree No. M/108, provides a comprehensive legal framework for the regulation of medicinal products, herbal preparations, and pharmaceutical operations in the Kingdom. This law, enforced by the Saudi Food and Drug Authority (SFDA), establishes the SFDA's full regulatory authority across the lifecycle of medicinal products, covering manufacturing, importing, exporting, product registration, marketing authorization, distribution, retail operations, and advertising oversight.

Salehiya Trading Company's product strategy focuses on advanced antibiotics and oncology treatments, with Meropenem, Vincristine, and Dacarbazine being the top imported products. This focus aligns with the growing demand for specialized healthcare solutions in Saudi Arabia, driven by an aging population and increasing prevalence of chronic diseases. By concentrating on these therapeutic areas, Salehiya aims to address critical healthcare needs and strengthen its position in the market.

Salehiya Trading Company's sourcing strategy emphasizes importing finished pharmaceutical formulations from India, particularly in the categories of advanced antibiotics and oncology treatments. This approach leverages India's established pharmaceutical manufacturing capabilities and cost advantages. The company's focus on a limited number of suppliers suggests a strategic choice to maintain quality control and supplier reliability. However, this concentration also exposes the company to potential risks, such as supply chain disruptions or pricing volatility.

Salehiya Trading Company's focus on advanced antibiotics and oncology treatments positions it to serve the specialized segments of the Saudi Arabian pharmaceutical market. By importing and distributing these high-demand products, the company caters to hospitals, specialized clinics, and healthcare providers requiring advanced therapeutic solutions. This strategic positioning allows Salehiya to address critical healthcare needs and strengthen its presence in the market.

For new Indian suppliers, there is a realistic opportunity to partner with Salehiya Trading Company, given the company's focus on advanced antibiotics and oncology treatments. Suppliers can explore avenues to diversify Salehiya's product portfolio within these therapeutic areas. However, potential suppliers should be aware of the risks associated with high supplier concentration and consider strategies to mitigate these risks.

Indian exporters seeking to supply Salehiya Trading Company and the Saudi Arabian market must ensure compliance with the Saudi Food and Drug Authority's (SFDA) regulations. This includes obtaining a Certificate of Free Sale from the exporting country's Department of Health and Human Services and ensuring that products meet SFDA's quality standards, including Good Manufacturing Practice (GMP) certifications from recognized international bodies. Additionally, products must be registered with the SFDA before importation.

Indian exporters interested in supplying Salehiya Trading Company should initiate contact through the company's official channels, providing detailed product information and demonstrating compliance with SFDA regulations. Participating in tenders and engaging in direct communication can facilitate the establishment of a partnership. Understanding the regulatory requirements and ensuring timely product registration with the SFDA are crucial steps in the process. Establishing a relationship with Salehiya may involve navigating the competitive landscape, but with a focus on quality and compliance, Indian exporters can position themselves as valuable partners.